Chronic graft-versus-host disease (GVHD) is the most common late complication following allogeneic stem cell transplantation, occurring in 25-80% of transplant recipients. 1 It is becoming a more frequent problem due to the increasing recipient age at transplantation as well as the increasing use of alternative donors, peripheral blood stem cells, and donor lymphocyte infusions. The most widely employed first line therapy for chronic GVHD is a combination of cyclosporine (CSA) and prednisolone, but patients who failed to respond to the initial steroid-based therapy have a poor outcome. 1 Therefore, various agents have been investigated as salvage therapy for chronic GVHD, but there is no standard approach that is uniformly accepted.
Anti-CD20 antibody (rituximab) is a chimeric mouse-human immunoglobulin G antibody, mediating B-cell lysis by complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis. It was developed for the treatment of B-cell malignancies but has also shown efficacy in the treatment of a variety of autoimmune diseases. 2 Chronic GVHD has characteristics of not only immunodeficiency but also autoimmunity. A recent report on anti-B-cell therapy with rituximab for thrombocytopenia in a single patient with chronic GVHD showed that apart from the recovery of thrombocytopenia, severe xerostomia of the patient also responded. 3 We therefore started a clinical trial of rituximab for sclerodermatous chronic GVHD after approval of the institutional review board and written informed consent from the patient had been obtained. Three patients with progressive extensive type chronic GVHD were included in this study (Table 1 ). These subjects consisted of one male and two females aged between 33 and 42 years. All patients were in complete remission of their hematological malignancies. Rituximab was given 375 mg/m 2 intravenously weekly four times, and the dose of immunosuppressive drugs previously prescribed was not changed during rituximab treatment. Cutaneous GVHD was assessed quantitatively using modified Rodnan total skin thickness score (m-Rodnan TSS) on weeks 8 and 16, and was evaluated histologically by skin biopsy. Schirmer's test was performed when patients demonstrated ocular sicca syndrome. Complete blood counts, and immunological profiles including immunoglobulin levels, lymphocyte subsets and autoantibodies were performed at each visit. Case 1 had chronic GVHD with sclerodermatous skin involvement with erythema and pigmentation, resulting in flexion contracture. He also had oral ulceration, ocular sicca syndrome, bronchiolitis obliterans and abnormal liver function test. His GVHD was unresponsive to tacrolimus and PSL. At 3 months after initiation of rituximab therapy, his cutaneous GVHD was improved, and skin biopsy showed significant decrease of fibrous tissue without improvement of any other lesions. He developed repeated bacterial pneumonia 2.5 and 4.5 months after initiation of therapy, and died of septic shock. Case 2 had sclerodermatous cutaneous GVHD with erythema on her neck with ocular sicca syndrome and abnormal liver function test. At 2 months after initiation of rituximab therapy, her cutaneous GVHD was slightly improved, and skin biopsy showed slight decrease of fibrous tissue. However, elevated liver enzymes were not changed. She developed fever and hypoxemia 2 months after initiation of therapy, but hypoxemia was spontaneously improved. Case 3 had sclerodermatous cutaneous GVHD with pigmentation on her extremities with ocular sicca syndrome, oral ulceration and esophagitis. At 2 months after initiation of rituximab therapy, her cutaneous GVHD was improved, and skin biopsy showed significant decrease of fibrous tissue. However, other lesions were not changed. She developed interstitial pneumonitis 1.5 months after the initiation of therapy, but spontaneously recovered.
These observations suggested that rituximab was effective for steroid-refractory sclerodermatous chronic GVHD 2-3 months Letters to the Editor after initiation of therapy, but not for other lesions such as liver, eye or mouth. M-Rodnan TSS was improved in all patients. Cutaneous biopsy showed significant decrease of collagen fibers in all three patients (Figure 1 ). Although these observations were consistent with previous reports, there were no reports focusing on the immunological profiles. [3] [4] [5] In this study, immunoglobulin levels decreased slightly, and B cells were almost completely depleted. Furthermore, a significant number of lymphocytes other than B cells decreased. It is unclear why B-cell depletion is effective for sclerodermatous cutaneous GVHD. In this study, cutaneous biopsy showed a slight infiltration of inflammatory cells in the skin lesion, therefore B cell is not thought to cause scleroderma directly. Some cytokines such as TGF-b or IL-4 were known to upregulate fibroblast proliferation, and the TGFb1 level was elevated in patients with chronic GVHD, and was correlated with its severity. 6 It is therefore important to measure these cytokine levels in the course of treatment, as skin sclerosis might be improved by the reduction of these cytokines.
Since various autoantibodies are often detected in patients with chronic GVHD, there is dysregulation of humoral immunity in chronic GVHD. And since B cell is a precursor of antibody-producing cell, B-cell depletion is considered to improve dysregulation of humoral immunity. This mechanism may be important for diseases in which autoantibody is the main cause, such as autoimmune thrombocytopenic purpura or autoimmune hemolytic anemia. 2 While B cell is an antigenpresenting cell, and interacts with either CD8 þ or CD4 þ T cell via MHC class I or II, it is particularly important for autoreactive B cell to interact with CD4 þ T cell, because CD4 þ T cell activated by autoreactive B cell cause more complex dysregulation of cellular and humoral immunity. Indeed, several reports showed that most patients with chronic GVHD show evidence of B-cell activation. 7 In our study, total lymphocytes were more severely decreased in number than B cells, even though rituximab has been considered to deplete B cell only. Therefore, rituximab may suppress T cells that interact with activated B cells. Moreover, various cytokines such as IL-1, IL-6, IL-10 or IL12 are secreted from B cell, and B cell interacts with other components of the lymphocyte population. Therefore, immune dysregulation in chronic GVHD may be improved by resetting B cells. However, other causes of immune dysregulation must exist, because rituximab had little effect on other lesions.
In our study, all patients developed fever, and one patient died of septic shock after repeated infections. This suggests that rituximab treatment has considerable immunosuppressive effect for patients with chronic GVHD. The patient who died probably developed a severe immunodeficiency, since severe lymphocytopenia and hypogammaglobulinemia were seen in this patient. Therefore, monitoring of life-threatening infections is necessary for severely immunodeficiency patients with chronic GVHD.
Rituximab is effective for sclerodermatous chronic GVHD, and is useful as special devices are not needed unlike extracorporeal photopheresis. 8 However, it is not fully effective for extracutaneous chronic GVHD, and is considerably immunosuppresive. Further study is warranted to evaluate the efficacy and risk of rituximab therapy for refractory chronic GVHD. 
Figure 1
Skin biopsy before and after rituximab therapy. Microscopic findings before and after rituximab therapy in case 3 are shown.
Severe fibrosis was present in the lower dermis and was spreading to the subcutis. Fibrosis was often accompanied by hyalinization, but there were few inflammatory cells in this specimen. Skin biopsy 16 weeks after the initiation of treatment showed a significant reduction of fibrous tissue in the upper dermis.
